My watch list  

194 Current news of Evotec


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Merck Licenses CRISPR Gene-Editing Technology to Evotec

License to accelerate research, enable testing and development of new drugs


Merck announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use Merck’s CRISPR genome-editing technology to create edited cell lines ...


Evotec and Vifor Pharma form joint venture


Evotec SE and Vifor Pharma announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will gain ...


Evotec and Celmatix enter into strategic collaboration


Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, ...


Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian


Evotec SE announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. Aeovian and Evotec entered into a drug discovery partnership in 2017 to discover and develop new and highly selective ...


Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration


Evotec SE and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer. Under the terms of the collaboration agreement, Evotec received full access to the colorectal ...


Evotec and Takeda enter collaboration agreement to discover clinical candidates across multiple therapeutic areas


Evotec SE announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Under the collaboration, the parties aim to establish at least five drug discovery programmes with the goal of Evotec delivering clinical candidates for Takeda to pursue into ...


New IMI project “GNA NOW” kicks off its battle against antimicrobial resistance


Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterialagents: Gram-Negative Antibacterials NOW (“GNA NOW”). The new GNA NOW project, led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), will work ...


Evotec expands its iPSC discovery platform


Evotec SE announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform. The acquired assets include intellectual property relevant for iPSC-based phenotypic drug discovery, an existing cellular product business around iPSC-derived ...


Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"

Early stage funding amounting to € 30 m


Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint ...


Evotec completes acquisition of Just Biotherapeutics


Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics (“Just.Bio”), signed on 20 May 2019, has been completed. The acquisition accelerates Evotec’s long-term strategy to be the industry partner of choice for external end-to-end innovation, strengthening Evotec’s ...


Page 1 From 20
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE